SCHEMBL471834

SCHEMBL471834

O=C(C=Cc1ccc(O)c(O)c1O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.64
MAOB P27338 2/20 0.59
CAPN1 P07384 1/20 0.56
CTSL P07711 1/20 0.56
CTSB P07858 1/20 0.56
MAPT P10636 3/20 0.55
LMNA P02545 2/20 0.55
BCHE P06276 2/20 0.55
PLIN1 O60240 1/20 0.55
TNFRSF1A P19438 1/20 0.55
ACHE P22303 1/20 0.55
RECQL P46063 1/20 0.55
PLIN5 Q00G26 1/20 0.55
CYP1B1 Q16678 1/20 0.55
ABHD5 Q8WTS1 1/20 0.55
RAB9A P51151 2/20 0.53
CYP3A4 P08684 1/20 0.53
HSPD1 P10809 1/20 0.53
PKM P14618 1/20 0.53
NFKB1 P19838 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610336 1.00 TYR (0.64) TYRMAOBCAPN1CTSLCTSB
SCHEMBL30872967 0.86 IAPP (0.62) TYRMAOBMAPTLMNABCHE
SCHEMBL7925826 0.86 IAPP (0.62) TYRMAOBMAPTLMNABCHE
SCHEMBL1073514 0.86 IAPP (0.62) TYRMAOBMAPTLMNABCHE
SCHEMBL4460729 0.86 CHRNA7 (0.68) TYRMAOBCAPN1CTSLCTSB
SCHEMBL4460724 0.86 CHRNA7 (0.68) TYRMAOBCAPN1CTSLCTSB
SCHEMBL7191588 0.85 TYR (0.59) TYRMAOBCAPN1CTSLCTSB
SCHEMBL7191590 0.85 TYR (0.59) TYRMAOBCAPN1CTSLCTSB
SCHEMBL636139 0.85 TYR (0.62) TYRMAOBMAPTLMNABCHE
Hydrochloric Acid SCHEMBL4426609 0.85 IAPP (0.60) TYRMAOBMAPTLMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4496476-A1 GAS PHASE TREATMENT OF PRODUCE Apeel Technology, Inc. (US) 2025-01-29 EP claimed
CN-117320559-A Edible coating with antimicrobial properties 阿比尔技术公司 2023-12-29 CN claimed
WO-2023183341-A1 GAS PHASE TREATMENT OF PRODUCE APEEL TECHNOLOGY, INC. (US) 2023-09-28 WO claimed
CN-112176368-B Potassium chloride acidic zinc plating electroplating solution and application thereof 武汉奥邦表面技术有限公司 2021-07-09 CN claimed
CN-112176368-A Potassium chloride acidic zinc plating electroplating solution and application thereof 武汉奥邦表面技术有限公司 2021-01-05 CN claimed
CN-106107406-B Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers 弗门尼舍公司 2020-06-09 CN claimed
CN-109535118-A A kind of synthetic method of fisetin 陕西嘉禾生物科技股份有限公司 2019-03-29 CN claimed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US claimed
CN-108467699-A A kind of Optical adhesive composition and preparation method thereof 苏州盛达胶粘制品有限公司 2018-08-31 CN claimed
US-20170367974-A1 Polymer Implants For Treatment Of Metabolic Disorders UNIVERSITY OF SOUTH CAROLINA 2017-12-28 US claimed
EP-1954681-A2 COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT National Jewish Medical and Research Center (US) 2008-08-13 EP claimed
WO-2007073518-A9 COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT NAT JEWISH MED & RES CENTER (US) 2007-08-23 WO claimed
WO-2007073518-A2 COMPOUNDS AND METHODS FOR THIOL-CONTAINING COMPOUND EFFLUX AND CANCER TREATMENT NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2007-06-28 WO claimed
CN-1816328-A Therapeutic agent TAKARA BIO INC (JP) 2006-08-09 CN claimed
US-20060135585-A1 Compounds and methods for thiol-containing compound efflux and cancer treatment NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2006-06-22 US claimed
EP-1478757-A2 PRODUCTION OF DADZEIN IN TRANSGENIC PLANTS UNILEVER PLC (GB) 2004-11-24 EP claimed
WO-2003072790-A2 PRODUCTION OF DADZEIN IN TRANSGENIC PLANTS UNILEVER PLC (GB) 2003-09-04 WO claimed
CN-1087609-C Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumors INDENA SPA (IT) 2002-07-17 CN claimed
CN-1170362-A Chalcones and esters thereof with antiproliferative activity in uterus, ovary and breast tumours INDENA SPA (IT) 1998-01-14 CN claimed
CN-1095590-A By parasite or bacterial treatment of diseases and prevention STATENS SERUMINSTITUT (DK) 1994-11-30 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135585-A1 Compounds and methods for thiol-containing compound efflux and cancer treatment ABCC1, ABCC2, ABCB1 TYR 4795/4885MAOB 3654/4885CAPN1 2068/4885
US-20170367974-A1 Polymer Implants For Treatment Of Metabolic Disorders LRBA, FABP4, APMAP TYR 4660/4885MAOB 3615/4885CAPN1 4542/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 TYR 4427/4885MAOB 3735/4885CAPN1 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.